Literature DB >> 20083043

Deaths in custody: are some due to electronic control devices (including TASER devices) or excited delirium?

James R Jauchem1.   

Abstract

Deaths have occurred after law-enforcement incidents involving applications of electronic control devices (ECDs) (including TASER devices). An "excited delirium" syndrome (reported in the literature prior to the development of ECDs currently in use), however, includes several factors that may be related to such deaths in custody. In this review, potential detrimental effects of ECDs are compared with possible changes due to excited delirium. Although extreme (i.e., long-duration or repeated) exposures to ECDs can result in significant hyperkalaemia, acidaemia, and myoglobinemia in animal models, limited applications (such as those normally used in law-enforcement situations) would appear to have only transient effects. In addition, the hyperthermia observed in patients with excited delirium does not seem to be directly exacerbated by ECD applications. ECD use is unlikely to be a common cause of ventricular fibrillation, but other events that are generally associated with excited delirium (e.g., drug use) may be related to subsequent ventricular fibrillation or asystole. Metabolic or respiratory acidosis may only be serious consequences of long-duration or repeated ECD applications. On the basis of current available information, factors other than ECDs themselves may be more important when death occurs after the use of ECDs. 2009 Elsevier Ltd and Faculty of Forensic and Legal Medicine. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 20083043     DOI: 10.1016/j.jflm.2008.05.011

Source DB:  PubMed          Journal:  J Forensic Leg Med        ISSN: 1752-928X            Impact factor:   1.614


  11 in total

1.  Forensic standardizations in torture and death in custody investigations.

Authors:  Cristian Adrian Stan
Journal:  Interv Med Appl Sci       Date:  2012-12-27

Review 2.  Repeated or long-duration TASER electronic control device exposures: acidemia and lack of respiration.

Authors:  James R Jauchem
Journal:  Forensic Sci Med Pathol       Date:  2010-03       Impact factor: 2.007

Review 3.  TASER® conducted electrical weapons: misconceptions in the scientific/medical and other literature.

Authors:  James R Jauchem
Journal:  Forensic Sci Med Pathol       Date:  2014-12-31       Impact factor: 2.007

4.  Ongoing issues with the diagnosis of excited delirium.

Authors:  Roger W Byard
Journal:  Forensic Sci Med Pathol       Date:  2017-08-03       Impact factor: 2.007

Review 5.  Blood lactate concentration after exposure to conducted energy weapons (including TASER® devices): is it clinically relevant?

Authors:  James R Jauchem
Journal:  Forensic Sci Med Pathol       Date:  2013-04-19       Impact factor: 2.007

6.  Effects of a TASER® conducted energy weapon on the circulating red-blood-cell population and other factors in Sus scrofa.

Authors:  James R Jauchem; Joshua A Bernhard; Cesario Z Cerna; Tiffany Y Lim; Ronald L Seaman; Melissa Tarango
Journal:  Forensic Sci Med Pathol       Date:  2013-03-30       Impact factor: 2.007

7.  Physiological effects of the TASER C2 conducted energy weapon.

Authors:  James R Jauchem; Ronald L Seaman; Curtis M Klages
Journal:  Forensic Sci Med Pathol       Date:  2009-07-14       Impact factor: 2.007

Review 8.  The syndrome of excited delirium.

Authors:  James R Gill
Journal:  Forensic Sci Med Pathol       Date:  2014-02-14       Impact factor: 2.007

9.  Acute effects of an alternative electronic-control-device waveform in swine.

Authors:  James Jauchem; Charles W Beason; Michael C Cook
Journal:  Forensic Sci Med Pathol       Date:  2009-03-28       Impact factor: 2.007

10.  Quantifying underreporting of law-enforcement-related deaths in United States vital statistics and news-media-based data sources: A capture-recapture analysis.

Authors:  Justin M Feldman; Sofia Gruskin; Brent A Coull; Nancy Krieger
Journal:  PLoS Med       Date:  2017-10-10       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.